Patent intelligence · US
US 6956053
Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands
Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands
Patent details — US 6956053
- Jurisdiction
- US
- Status
- expired
- Grant date
- Oct 18, 2005
- Expiration
- Oct 13, 2025
- Applicant
- The James Black Foundation Limited
- Claims
- 40
- CPC classes
- A61K, A61K31/415, A61K31/4439, A61P
Quick answer
US 6956053 (Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands) is held by The James Black Foundation Limited. Status: expired. Granted Oct 18, 2005. Expires Oct 13, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- The James Black Foundation Limited
- Grant date
- Expiration
- Claims
- 40
- CPC classes
- A61K, A61K31/415, A61K31/4439, A61P, A61P1/04
More from The James Black Foundation Limited
Related pharmaceutical patents in our USPTO index.
-
US 12343394
CD38 modulating antibody agents
granted -
US 12325699
Antibacterial compounds
granted -
US 12304964
CD38 modulating antibody
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12161717
CD38 modulating antibody agents
granted -
US 12162949
CD38 antibody
granted -
US 11897873
Kappa opioid receptor antagonists and products and methods related thereto
granted -
US 11780930
CD38 modulating antibody
granted
Frequently asked questions
What is US patent 6956053?
US 6956053 (Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands) is held by The James Black Foundation Limited. Status: expired. Granted Oct 18, 2005. Expires Oct 13, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6956053?
The James Black Foundation Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 6956053 expire?
Our index shows an expiration date of Oct 13, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.